Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Liabilities and Shareholders Equity (2019 - 2025)

Korro Bio (KRRO) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $161.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 33.67% year-over-year to $161.5 million, compared with a TTM value of $770.4 million through Sep 2025, down 15.6%, and an annual FY2024 reading of $226.2 million, up 2.06% over the prior year.
  • Liabilities and Shareholders Equity was $161.5 million for Q3 2025 at Korro Bio, down from $180.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $249.6 million in Q2 2024 and bottomed at $46.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $172.8 million, with a median of $185.4 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 65.92% in 2023, then skyrocketed 425.45% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $185.4 million in 2021, then crashed by 60.22% to $73.7 million in 2022, then surged by 200.59% to $221.7 million in 2023, then grew by 2.06% to $226.2 million in 2024, then decreased by 28.59% to $161.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KRRO at $161.5 million in Q3 2025, $180.4 million in Q2 2025, and $202.2 million in Q1 2025.